Abstract

Nirsevimab ( Beyfortus ) for prevention of severe RSV disease in young children .

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Young Children
  • Prevention Of Disease
  • Severe Disease
  • Severe RSV Disease
  • Severe RSV
    • + Show 1 more

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Similar Papers

Recent developments in the treatment and prevention of respiratory syncytial virus infection
  • Expert Opinion on Therapeutic Patents
  • Mar 1, 2002
Relevant
Not Relevant
Respiratory Syncytial Virus Prophylaxis
  • NeoReviews
  • Jan 1, 2005
Relevant
Not Relevant
Cold Weather Viruses
  • Pediatrics In Review
  • Oct 1, 2019
Relevant
Not Relevant
Factors associated with increased risk of progression to respiratory syncytial virus-associated pneumonia in young Kenyan children*
  • Tropical Medicine & International Health
  • May 8, 2008
Relevant
Not Relevant
Monkeypox: Considerations as a New Pandemic Looms
  • Journal of Investigative Dermatology
  • Oct 1, 2022
Relevant
Not Relevant
Altered gut microbiota in infants is associated with respiratory syncytial virus disease severity
  • BMC Microbiology
  • Jun 1, 2020
Relevant
Not Relevant
Age-Related Pathology Associated with H1N1 A/California/07/2009 Influenza Virus Infection
  • The American Journal of Pathology
  • Dec 1, 2019
Relevant
Not Relevant
Development of China's health care system in the time of COVID‐19: Challenges, opportunities, and call for actions
  • Health Care Science
  • Jul 26, 2022
Relevant
Not Relevant
Clostridium difficile Infections in Children
  • Pediatric Infectious Disease Journal
  • Feb 1, 2009
Relevant
Not Relevant
Editorial - Respiratory Syncytial Virus Infection in High-Risk Infants
  • The Open Microbiology Journal
  • Dec 30, 2011
Relevant
Not Relevant
Respiratory syncytial virus infection in high-risk infants.
  • The open microbiology journal
  • Jan 1, 2011
Relevant
Not Relevant
Pediatric multidrug-resistant tuberculosis clinical trials: challenges and opportunities
  • International Journal of Infectious Diseases
  • Mar 1, 2017
Relevant
Not Relevant
Choices abound for 2013–14 influenza season
  • Pharmacy Today
  • Aug 1, 2013
Relevant
Not Relevant
Identification of novel factors associated with severe respiratory syncytial virus disease in infants
  • Access Microbiology
  • Mar 1, 2019
Relevant
Not Relevant
Relationship of HLA-DQ8 and severity of celiac disease: Comparison of New York and Parisian cohorts
  • Clinical Gastroenterology and Hepatology
  • Oct 1, 2004
Relevant
Not Relevant
READ MORE FROM

The Medical letter on drugs and therapeutics

Nirsevimab (Beyfortus) for prevention of severe RSV disease in young children.
Just Published
  • The Medical letter on drugs and therapeutics
  • Sep 18, 2023
Relevant
Not Relevant
Comparison table: Some drugs for maintenance treatment of opioid use disorder.
  • The Medical letter on drugs and therapeutics
  • Sep 4, 2023
Relevant
Not Relevant
Niraparib/abiraterone acetate (Akeega) for prostate cancer.
  • The Medical letter on drugs and therapeutics
  • Sep 4, 2023
Relevant
Not Relevant
Lecanemab (Leqembi) granted full approval for early Alzheimer's disease.
  • The Medical letter on drugs and therapeutics
  • Aug 21, 2023
Relevant
Not Relevant
Linaclotide (Linzess) for functional constipation.
  • The Medical letter on drugs and therapeutics
  • Aug 21, 2023
Relevant
Not Relevant
Relugolix (Orgovyx) for advanced prostate cancer.
Open Access
  • The Medical letter on drugs and therapeutics
  • Jul 24, 2023
Relevant
Not Relevant
Table: Some drug interactions with drugs for IBD.
  • The Medical letter on drugs and therapeutics
  • Jul 24, 2023
Relevant
Not Relevant
Tofersen (Qalsody) for ALS.
  • The Medical letter on drugs and therapeutics
  • Jul 24, 2023
Relevant
Not Relevant
Inspire for obstructive sleep apnea.
  • The Medical letter on drugs and therapeutics
  • Jul 24, 2023
Relevant
Not Relevant
Sotagliflozin (Inpefa) for heart failure.
  • The Medical letter on drugs and therapeutics
  • Jul 24, 2023
Relevant
Not Relevant